Therefore, understanding the secretion of TGF-β, which is defined as a mediator of the switch from a tumor-suppressive to a pro-oncogenic status, after galunisertib treatment is central to understanding the influence of galunisertib on tumorigenesis. This evidence concerns the gene TGFB1 and neoplasm.